Analysis of lung transplant recipients surviving beyond 5 years.
BACKGROUND
We started lung transplantation (LT) in October 1993 and review the status of recipients who have survived beyond 5 years.


METHODS
A retrospective review of patients undergoing LT from October 1993 to October 1998 included pulmonary function data, incidence of bronchiolitis obliterans syndrome (BOS), functional status, and survival.


RESULTS
Of 73 transplantations 41 (56%) patients have survived beyond 5 years (study group), including 23 men and 18 women of age 33.2 +/- 15.6 years. Indications for LT were as follows: cystic fibrosis (n = 16), emphysema (n = 13), pulmonary fibrosis (n = 8), and other (n = 4). Actuarial survival at 5, 7, and 9 years was 56%, 53%, and 43%, respectively. Freedom from BOS was 63%, 56%, and 50% at 5, 7, and 9 years, respectively. The median percent predicted FEV1 was 67%, 56%, and 56%, respectively. Also, 79% of recipients had no limitations in their daily activities; 65% were active and working. Only 5% of patients showed some degree of limitation at 5 years posttransplantation. When survivors beyond 5 years were compared with nonsurvivors beyond 5 years, differences were observed: nonsurvivors more frequently required bypass (P = .01), experienced longer postoperative intubation times (P = .01), and exhibited lower PaO2 at 12 months posttransplantation (P < .01).


CONCLUSIONS
Our data show good survival rates among patients surviving beyond 5 years after LT, with a moderate incidence of BOS at 9 years posttransplantation. Despite the incidence of BOS, these patients have good pulmonary function and activity status.
Lama
R
R
Department of Respiratory Medicine, Lung Transplantation Unit, University Hospital Reina Sofia, Córdoba, Spain. rafael.lama.sspa@juntadeandalucia.es
Santos
F
F
Alvarez
A
A
Algar
F J
FJ
Baamonde
C
C
Quero
F
F
Cerezo
F
F
Salvatierra
A
A
D000206:Actuarial Analysis; D000328:Adult; D001989:Bronchiolitis Obliterans / Q000453:epidemiology*; D005260:Female; D005500:Follow-Up Studies; D005541:Forced Expiratory Volume; D006801:Humans; D016040:Lung Transplantation / Q000401:mortality / Q000502:physiology*; D008297:Male; D011183:Postoperative Complications / Q000453:epidemiology*; D012129:Respiratory Function Tests; D012189:Retrospective Studies; D013534:Survival; D016019:Survival Analysis; D013997:Time Factors